GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Maccura Biotechnology Co Ltd (SZSE:300463) » Definitions » Debt-to-EBITDA

Maccura Biotechnology Co (SZSE:300463) Debt-to-EBITDA : 6.29 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Maccura Biotechnology Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Maccura Biotechnology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥602 Mil. Maccura Biotechnology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥251 Mil. Maccura Biotechnology Co's annualized EBITDA for the quarter that ended in Mar. 2025 was ¥136 Mil. Maccura Biotechnology Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was 6.29.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Maccura Biotechnology Co's Debt-to-EBITDA or its related term are showing as below:

SZSE:300463' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.42   Med: 1.05   Max: 22.02
Current: 22.02

During the past 13 years, the highest Debt-to-EBITDA Ratio of Maccura Biotechnology Co was 22.02. The lowest was 0.42. And the median was 1.05.

SZSE:300463's Debt-to-EBITDA is ranked worse than
97.2% of 107 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.68 vs SZSE:300463: 22.02

Maccura Biotechnology Co Debt-to-EBITDA Historical Data

The historical data trend for Maccura Biotechnology Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maccura Biotechnology Co Debt-to-EBITDA Chart

Maccura Biotechnology Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.09 0.75 0.64 1.02 1.36

Maccura Biotechnology Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 2.20 2.05 -0.92 6.29

Competitive Comparison of Maccura Biotechnology Co's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Maccura Biotechnology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maccura Biotechnology Co's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Maccura Biotechnology Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Maccura Biotechnology Co's Debt-to-EBITDA falls into.


;
;

Maccura Biotechnology Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Maccura Biotechnology Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(466.381 + 190.909) / 483.351
=1.36

Maccura Biotechnology Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(601.979 + 251.401) / 135.652
=6.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.


Maccura Biotechnology Co  (SZSE:300463) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Maccura Biotechnology Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Maccura Biotechnology Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Maccura Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
Number 8, 2nd Anhe Road, Hi-tech Zone, Chengdu, CHN, 611731
Maccura Biotechnology Co Ltd is a China-based in-vitro diagnostic (IVD) integration company engaged in the research and development, production and sales of IVD products. It is also engaged in the sales of foreign brands of in vitro diagnostic products as an agent. The company's developed product and technology development platforms cover clinical biochemistry, chemiluminescent immunoassay, rapid diagnosis, thrombosis, hemostasis, and molecular diagnosis.
Executives
Guo Lei Director
Wang Deng Ming Directors, executives
Wang Lin Supervisors
Wu Ming Jian Directors, executives
Shi Wei Directors, executives
Yang Hui Supervisors
Zhou Yue Guo Executives
Wang Zhen Executives
Yu Ping Executives
Zou Yuan Supervisors
Xu Sheng Guo Directors, executives
Liu Qi Lin Directors, executives
Chu Jian Jun Executives
Tang Yong Director
Xu Jin Song Executives

Maccura Biotechnology Co Headlines

No Headlines